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Mean HbA1c levels during follow-up for subjects with normal and elevated HbA1c level at baseline
Normal baseline HbA1c
(< 42 mmol/mol)
Elevated baseline HbA1c
( 42 mmol/mol)
Placebo Glucosamine Placebo Glucosamine
Baseline N (%) 150 (74%) 156 (76%) 43 (21%) 32 (16%)
HbA1c (mmol/mol) 36.7  2.9 37.1  2.8 50.6  11.1 51.6  16.8
1 year N (%) 124 (66%) 129 (63%) 36 (18%) 29 (14%)
HbA1c (mmol/mol) 37.2  2.8 37.8  3.0 48.1  9.9 48.9  12.9
2.5 years N (%) 131 (71%) 136 (66%) 34 (17%) 26 (13%)
HbA1c (mmol/mol) 37.3  2.8 37.8  3.7 48.6  12.5 50.2  11.8
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S461available for 94% of all subjects at baseline, 78% after 1 year and 80%
after 2.5 years. The glucosamine intervention had a non-signiﬁcant
effect on mean HbA1c level over 2.5 years, when analysed among all
subjects (p ¼ 0.94), and in subjects with a normal (p ¼ 0.60) or elevated
(p ¼ 0.82) HbA1c level at baseline (see table for stratiﬁed mean HbA1c
values over the follow-up period). However, compared to placebo,
subjects randomized to glucosamine sulphate had a signiﬁcantly
increased risk for attaining an elevated HbA1c level at follow-up (odds
ratio 2.81 [95% CI 1.12 - 7.04]).
Conclusions: A 2.5 year oral glucosamine sulphate intervention did not
affect mean HbA1c levels in overweight and obese women, but did lead
to signiﬁcant more womenwith increased levels of HbA1c ( 42 mmol/
mol). This HbA1c level is known to put people at ‘high risk for devel-
oping diabetes’. Long-term follow-up should demonstrate whether
these women will indeed develop diabetes at a higher rate and thus,
whether this should be considered as a true side effect of glucosamine
within this population.
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RADIOLOGICAL PROGRESSORS FROM THE FIRST YEAR IN SEKOIA
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One of the most important issues in the studies of chondroprotection
is to be able to extrapolate a decrease in structural evolution into a
delay in knee surgeries such as joint replacement, as studies are
usually not long enough to provide this answer. Nevertheless, rapid
progressors on a short period of time (Group for the Respect of Ethics
and Excellence in Science (GREES) criteria) could help providing an
answer as these patients have been shown to be at higher risk of
surgeries.
Objective(s): The aim of this post hoc analysis is to describe the efﬁcacy
of Strontium Ranelate (SrRan) on rapid radiological progression, from
the ﬁrst year, in patients from SEKOIA study (randomised study with 3
years of treatment by 2 doses of SrRan versus placebo in knee
osteoarthritis).
Material and methods: 1683 patients suffering from symptomatic
primary knee osteoarthritis (Kellgren and Lawrence [KL] score of 2 or 3,
joint space width (JSW) of 2.5 to 5 mm and pain assessed on a visual
analogue scale of at least 40 mm) have been included and randomised
to receive SrRan 1 g/day, 2 g/day or placebo during 3 years. Knee X-rays
were performed yearly during 3 years, with a validated semi-automated
method of joint space narrowing (JSN) assessment. During the ﬁrst year,
radiological progressors (deﬁned as having a JSN  0,3 or  0,5 mm;
over the SDD), have been compared between groups using a Chi2 test in
the ITT population.
Results: ITT set included 1371 patients (82% of the randomized set;
445 patients in SrRan 1g group, 454 patients in SrRan 2g group and
472 patients in placebo group) with a mean age of 637 years, a mean
BMI of 305 kg/m2 and a mean JSW of 3.50.8 mm. 61% of patients
were KL II and 69% were female. A signiﬁcantly lower proportion of
patients in SrRan1g and 2g groups had radiological progression duringthe ﬁrst year compared to placebo: 12% and 13% versus 30%. The
estimate of the between groups difference E (SE) was -8.07 (2.42), 95%
CI [-12.81; -3.33] with p < 0.001 for SrRan 1g/d versus placebo and E
(SE) was -6.91 (2.45), 95% CI [-11.71; -2.10] with p ¼ 0.005 for SrRan
2g/d versus placebo. It corresponds to a decrease of the risk of rapid
progression by 40% and 35% in the SrRan 1g and 2g groups compared
to placebo
Conclusion: In patients suffering from primary knee OA, SrRan at the
dose of 1g or 2g/d decreases the number of rapid radiological pro-
gressors from the ﬁrst year of treatment suggesting that the beneﬁcial
structural effect could be clinically relevant.
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Purpose: Osteoarthritis is a high prevalence disease characterized by a
progressive loss of articular cartilage. Cartilage degradation is asso-
ciated with structural and metabolic changes in joint tissues such as
cartilage, subchondral bone and synovial membrane inﬂammation. One
reliable model to investigate the natural course of the disease and to
study the effects of treatments is Dunkin-Hartley guinea pigs devel-
oping spontaneous knee osteoarthritis which mimics the pathophy-
siological processes of human osteoarthritis. The potential protective
effects of three polyphenols found in olive oil (oleuropein) or fruits and
vegetables (rutin and curcumin) were assessed on this joint ageing and
osteoarthritis development model.
Methods: Sixty four-week old Dunkin-Hartley guinea pigs were random-
ized into four groups and received daily during 31 weeks either standard
guinea pig diet (control group) or a standard guinea pig diet enrichedwith
oleuropein (0.025 %), rutin (0.5%) or rutin/curcumin (0.5% / 0.25%) associ-
ation. Animals were weighed each week and blood samples taken every 6
weeksandat thetimeof euthanasia (week35).Biomarkersofosteoarthritis
(COLL2-1, COLL2-1NO2, Fib3-1, Fib3-2) as well as inﬂammation (PGE2)
were quantiﬁed in the serum. Histological assessments of knee cartilage
and synovial membrane were performed at week 35.
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developed signiﬁcant cartilage lesions with mild synovial inﬂamma-
tion. The histological scores of cartilage lesions and synovitis were
well correlated with the increased level of serum biomarkers. Histo-
logically, all treatments signiﬁcantly reduced the cartilage degradation
score (p < 0.01), but only oleuropein signiﬁcantly decreased synovitis
(p < 0.05) compared to the control group. Furthermore, oleuropein
decreased serum PGE2 levels at week 35 (p < 0.01). Serum COLL2-1
and Fib3-1 were decreased by rutin and the combination of rutin and
curcumin, Fib3-2 was only decreased by the combination of rutin and
curcumin, while COLL2-1NO2 was signiﬁcantly decreased by all
treatments (p < 0.05).
Conclusions: Oleuropein and rutin with or without curcumin sig-
niﬁcantly slowed down the progression of spontaneous osteoarthritis
lesions in guinea pigs. While no additive effect was seen in the curcu-
min and rutin group, the differential effects of oleuropein or rutin on
inﬂammatory and cartilage catabolic markers suggest an interesting
combination for future studies in osteoarthritis protection.
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THE SELECTIVE CATHEPSIN K INHIBITOR MIV-711 PREVENTS
SUBCHONDRAL AND CANCELLOUS BONE LOSS IN RABBITS
SUBJECTED TO ANTERIOR CRUCIATE LIGAMENT TRANSECTION
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Purpose: Subchondral bone is often affected in osteoarthritis patients.
These abnormalities can be manifested as subchondral bone loss, bone
sclerosis, bone marrow lesions and osteophyte formation depending on
disease stage. We evaluated the effect of anterior cruciate ligament
transection (ACLT) on subchondral and cancellous bone in rabbits and
whether the selective cathepsin K inhibitor MIV-711 could reverse the
ACLT-evoked changes.
Methods: New Zealand white rabbits aged 9-10 months old were
subjected to ACLT (n ¼ 21) or sham surgery (n ¼ 6) of the right
femorotibial joint. One week after surgery, ACLT rabbits were treated
with either vehicle (n ¼ 7), 30 mmol/kg (n ¼ 7), or 100 mmol/kg MIV-
711 (n ¼ 7), while the sham group received vehicle. Treatments were
given orally once daily for 7 weeks until sacriﬁce. Plasma samples
were collected on Days 1, 10, 22 and 45 for determination of MIV-711
concentrations. After sacriﬁce, subchondral bone parameters were
quantiﬁed using mCT.
Results: Treatment with MIV-711 resulted in a dose-dependent
increase in circulating concentrations of MIV-711. Similar pharmaco-
kinetic proﬁles were seen on each day assessed. ACLTcaused thinning of
the subchondral bone plate that was dose-dependently reversed by
MIV-711. Figure 1 shows subchondral bone plate thickness repre-
sentative of the group mean values for average plate thickness. ACLT
evoked a 14% loss in femur subchondral bone plate thickness compared
to the vehicle-treated sham group (sham: 346 6 mmvs. ACLT: 296 16
mm, p < 0.05).
The bone loss induced by ACLT was reversed by MIV-711 (30 mmol/kg:
347  10 mm; 100 mmol/kg: 353  8 mm, p < 0.05 vs. ACLT vehicle forFigure 1. Representative subchondral bone thickness maps.Ăboth groups). Similar ﬁndings were found when assessing femur
subchondral bone plate volume (sham: 50.8  2.5 mm3 vs. ACLT:
45.5 3.1 mm3) with full reversal by MIV-711 (30 mmol/kg: 53.7  0.8
mm3; 100 mmol/kg: 55.6  2.0 mm3, p < 0.05 vs. ACLT vehicle for both
groups). ACLT also caused a 15% decrease in tibial subchondral bone
plate thickness (sham: 383  19 mm vs. ACLT: 324  14 mm, p < 0.05)
which was reversed by MIV-711 (30 mmol/kg: 383  15 mm; 100 mmol/
kg: 401  8 mm, p < 0.05 vs. ACLT vehicle for both groups). Tibial
subchondral bone volume was decreased by 17% in response to ACLT
(sham: 40.3  1.1 mm3 vs. ACLT: 33.4  1.7 mm3) with full reversal by
MIV-711 (30 mmol/kg: 39.0  2.0 mm3; 100mmol/kg: 41.2  0.9 mm3, p
< 0.05 vs. ACLT vehicle for both groups). In general, the bone loss was
most pronounced in lateral sites. Similar trends were seen when
evaluating the bone volume fraction (BV/TV) of cancellous bone
although with larger variation. Again, the highest degree of ACLT-
evoked bone loss was seen in lateral sites. MIV-711 attenuated can-
cellous bone loss in the lateral femur (BV/TV; sham: 0.383  0.020;
ACLT: 0.312  0.018; 30 mmol/kg: 0.342  0.029; 100 mmol/kg: 0.357 
0.013) and fully prevented cancellous bone loss in the lateral tibia (BV/
TV; sham: 0.497  0.028; ACLT: 0.376  0.031; 30 mmol/kg: 0.460 
0.034; 100 mmol/kg: 0.481  0.020, p < 0.05 vs. ACLT vehicle for 100
mmol/kg group).
Conclusions: The results demonstrate that ACLT, a preclinical rabbit
model of osteoarthritis, causes signiﬁcant bone loss in the subchondral
bone plate and in subchondral cancellous bone in both femur and tibia.
The bone loss is reversed by the selective cathepsin K inhibitor MIV-711
at clinically relevant concentrations.
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Purpose: Interleukin-1 (IL-1) is a potent catabolic cytokine thought to
play a major role in the development and progression of osteoarthritis
(OA) both in terms of disease (structural progression) and symptoms
(pain and functional deterioration). In a mouse model of OA, simulta-
neous inhibition of IL-1a and IL-1b with mouse anti-IL-1a/b dual vari-
able domain-immunoglobulin (DVD-Ig) reduced OA progression to a
greater extent than inhibition of either isoform alone, supporting
investigation of this mechanism of action in human trials for OA disease
modiﬁcation. The current objective is to review 2 completed phase 1
clinical trials and the protocol of a phase 2 trial investigating the use of a
novel human DVD-Ig targeting IL-1a and IL-1b (ABT-981).
Methods: The ﬁrst study in humans was a phase 1, randomized, double-
blind (DB), dose escalating, placebo-controlled study designed to assess
safety, tolerability, pharmacokinetics (PK), and anti-drug antibody
(ADA) formation following a range of dose levels of ABT-981/placebo
administered via a single intravenous (IV) infusion or subcutaneous (SC)
injection in 56 healthy subjects. The second trial was a randomized, DB,
multiple ascending dose (MAD), placebo-controlled study to assess the
safety, tolerability, PK and pharmacodynamics (PD) of multiple SC
injections of ABT-981 in knee OA patients. Patients (N ¼ 36) received
either 4 doses of placebo/ABT-981 every 2 weeks (E2W) or 3 doses
every 4 weeks. PD effects were measured by a list of biomarkers in the
areas of inﬂammation, joint destruction, and remodeling (eg, serum
hsCRP, MMP9, VEGF, C1M, C2M, C3M, CRPM, VICM, and neutrophils).
Results: ABT-981 was well tolerated in healthy subjects and knee OA
patients.NoapparentADAeffect onABT-981PKand safetywasobserved in
either phase 1 trial. The adverse event proﬁle did not signiﬁcantly differ
